STAT News: Investment in Antimicrobials Was Up in 2020, But Much Work Remains

Prior to 2019, the vaccine and anti-infective space was seen as a difficult space for emerging companies to flourish. In 2020, everything changed. Our managing director and anti-infectives expert, Dr. Pete Bak writes for STAT about the investment of vaccines, anti-infectives and the influx of cash when it comes to developing anti-microbials.

Read more in STAT

Back Bay in the NewsBack Bay Life Science AdvisorsAnti-Infectives, Vaccines, Funding, Emerging BioPharma, Commercial Development